Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574

VIROGATES A/S

(VIRO)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about VIROGATES A/S
12/08VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
12/06ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
12/03FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
12/01ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
11/29NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
11/11Interim Report – Q1-Q3, 2021
PU
11/11VIROGATES ANNOUNCES ITS INTERIM REPO : Revenue growth of 66% for the first nine months of ..
AQ
11/11ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/11ViroGates announces a delay in the development and launch of its pipeline product suPAR..
AQ
11/11ViroGates A/S Announces Delay in the Development of suPARnostic? POC+
CI
11/10Invitation to ViroGates' Q3 2021 presentation
AQ
11/05Elevated preoperative suPAR is a strong and independent risk marker for postoperative c..
PU
10/25VIROGATES A/S : announces a new hospital as a clinical routine customer in Greece
AQ
10/25ViroGates A/S Announces New Hospital as Clinical Routine Customer in Greece
CI
10/21VIROGATES A/S : SuPAR is associated with risk for thromboembolic complications and mortali..
PU
More most relevant news
All news about VIROGATES A/S
12/08VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
12/06ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
12/03FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
12/01ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
11/29NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
11/11Interim Report – Q1-Q3, 2021
PU
11/11VIROGATES ANNOUNCES ITS INTERIM REPO : Revenue growth of 66% for the first nine months of ..
AQ
11/11ViroGates A/S Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
CI
11/11ViroGates announces a delay in the development and launch of its pipeline product suPAR..
AQ
11/11ViroGates A/S Announces Delay in the Development of suPARnostic? POC+
CI
More news
News in other languages on VIROGATES A/S
04/29ViroGates A/S fournit des prévisions de revenus pour l'année 2021
More news
Press releases
12/08VIROGATES A/S : SuPAR independently predicts severity and length of hospitalisation in pat..
PU
12/06ViroGates announces a development, supply and collaboration agreement with Italy-based ..
AQ
12/03FRONTIERS IN IMMUNOLOGY PUBLICATION : Soluble Urokinase Plasminogen Activator Receptor (su..
PU
12/01ViroGates awarded a 2.8 DKKm Innobooster grant by The Innovation Fund Denmark to finali..
AQ
11/29NATURE MEDICINE PUBLICATION : Early anakinra treatment for COVID-19 guided by suPAR saves ..
PU
More press releases
Upcoming event on VIROGATES A/S
03/30/22